Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Helical tomotherapy for spine oligometastases from gastrointestinal malignancies

  • Choi, Yun-Seon (Department of Radiation Oncology, Yonsei University Health System) ;
  • Kim, Jun-Won (Department of Radiation Oncology, Yonsei University Health System) ;
  • Lee, Ik-Jae (Department of Radiation Oncology, Yonsei University Health System) ;
  • Han, Hee-Ji (Department of Radiation Oncology, Yonsei University Health System) ;
  • Baek, Jong-Geal (Department of Radiation Oncology, Yonsei University Health System) ;
  • Seong, Jin-Sil (Department of Radiation Oncology, Yonsei University Health System)
  • Received : 2011.07.07
  • Accepted : 2011.08.30
  • Published : 2011.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: This study evaluated the treatment effectiveness and proper radiation dose of helical tomotherapy (HT) in spine oligometastases from gastrointestinal cancers. Materials and Methods: From 2006 to 2010, 20 gastrointestinal cancer patients were treated with HT for spine oligometastases (31 spine lesions). The gross tumor volume (GTV) was the tumor evident from magnetic resonance imaging images fused with simulation computed tomography images. Clinical target volume (CTV) encompassed involved vertebral bodies or dorsal elements. We assumed that the planning target volume was equal to the CTV. We assessed local control rate after HT for 31 spine metastases. Pain response was scored by using a numeric pain intensity scale (NPIS, from 0 to 10). Results: Spine metastatic lesions were treated with median dose of 40 Gy (range, 24 to 51 Gy) and median 5 Gy per fraction (range, 2.5 to 8 Gy) to GTV with median 8 fractions (range, 3 to 20 fraction). Median biologically equivalent dose (BED, ${\alpha}/{\beta}$ = 10 Gy) was 52 $Gy_{10}$ (range, 37.5 to 76.8 $Gy_{10}$) to GTV. Six month local control rate for spine metastasis was 90.3%. Overall infield failure rate was 15% and outfield failure rate was 75%. Most patients showed pain relief after HT (93.8%). Median local recurrence free survival was 3 months. BED over 57 $Gy_{10}$ and oligometastases were identified as prognostic factors associated with improved local progression free survival (p = 0.012, P = 0.041). Conclusion: HT was capable of delivering higher BED to metastatic lesions in close proximity of the spinal cord. Spine metastases from gastrointestinal tumors were sensitive to high dose radiation, and BED (${\alpha}/{\beta}$ = 10 Gy) higher than 57 $Gy_{10}$ could improve local control.

Keywords

References

  1. Ratliff JK, Cooper PR. Metastatic spine tumors. South Med J 2004;97:246-53. https://doi.org/10.1097/01.SMJ.0000053923.35326.0D
  2. Foro Arnalot P, Fontanals AV, Galceran JC, et al. Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30 Gy in 10 fractions compared with 8 Gy in single fraction. Radiother Oncol 2008;89:150-5. https://doi.org/10.1016/j.radonc.2008.05.018
  3. Kaizu T, Karasawa K, Tanaka Y, et al. Radiotherapy for osseous metastases from hepatocellular carcinoma: a retrospective study of 57 patients. Am J Gastroenterol 1998;93:2167-71. https://doi.org/10.1111/j.1572-0241.1998.00614.x
  4. Sahgal A, Bilsky M, Chang EL, et al. Stereotactic body radiotherapy for spinal metastases: current status, with a focus on its application in the postoperative patient. J Neurosurg Spine 2011;14:151-66. https://doi.org/10.3171/2010.9.SPINE091005
  5. Thariat J, Marcy PY, Lagrange JL. Trends in radiation therapy for the treatment of metastatic and oligometastatic disease in 2010. Bull Cancer 2010;97:1467-76.
  6. Song DY, Kavanagh BD, Benedict SH, Schefter T. Stereotactic body radiation therapy. Rationale, techniques, applications, and optimization. Oncology (Williston Park) 2004;18:1419-30.
  7. Chang EL, Shiu AS, Lii MF, et al. Phase I clinical evaluation of near-simultaneous computed tomographic image-guided stereotactic body radiotherapy for spinal metastases. Int J Radiat Oncol Biol Phys 2004;59:1288-94. https://doi.org/10.1016/j.ijrobp.2004.04.025
  8. Ryu SI, Chang SD, Kim DH, et al. Image-guided hypo-fractionated stereotactic radiosurgery to spinal lesions. Neurosurgery 2001;49:838-46.
  9. Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S42-9. https://doi.org/10.1016/j.ijrobp.2009.04.095
  10. Swarm R, Abernethy AP, Anghelescu DL, et al. Adult cancer pain. J Natl Compr Canc Netw 2010;8:1046-86. https://doi.org/10.6004/jnccn.2010.0076
  11. Sheehan JP, Jagannathan J. Review of spinal radiosurgery: a minimally invasive approach for the treatment of spinal and paraspinal metastases. Neurosurg Focus 2008;25:E18.
  12. Yamada Y, Lovelock DM, Bilsky MH. A review of imageguided intensity-modulated radiotherapy for spinal tumors. Neurosurgery 2007;61:226-35. https://doi.org/10.1227/01.NEU.0000279970.10309.B5
  13. Olsen JR, Robinson CG, El Naqa I, et al. Dose-response for stereotactic body radiotherapy in early-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011;81:3299-303.
  14. Sahgal A, Larson DA, Chang EL. Stereotactic body radiosurgery for spinal metastases: a critical review. Int J Radiat Oncol Biol Phys 2008;71:652-65. https://doi.org/10.1016/j.ijrobp.2008.02.060
  15. Sterzing F, Schubert K, Sroka-Perez G, Kalz J, Debus J, Herfarth K. Helical tomotherapy. Experiences of the first 150 patients in Heidelberg. Strahlenther Onkol 2008;184:8-14. https://doi.org/10.1007/s00066-008-1778-6
  16. Kim B, Soisson ET, Duma C, et al. Image-guided helical Tomotherapy for treatment of spine tumors. Clin Neurol Neurosurg 2008;110:357-62. https://doi.org/10.1016/j.clineuro.2007.12.024
  17. Mahan SL, Ramsey CR, Scaperoth DD, Chase DJ, Byrne TE. Evaluation of image-guided helical tomotherapy for the retreatment of spinal metastasis. Int J Radiat Oncol Biol Phys 2005;63:1576-83. https://doi.org/10.1016/j.ijrobp.2005.05.015
  18. Milano MT, Zhang H, Metcalfe SK, Muhs AG, Okunieff P. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat 2009;115:601-8. https://doi.org/10.1007/s10549-008-0157-4
  19. Milano MT, Katz AW, Schell MC, Philip A, Okunieff P. Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2008;72:1516-22. https://doi.org/10.1016/j.ijrobp.2008.03.044
  20. Milano MT, Philip A, Okunieff P. Analysis of patients with oligometastases undergoing two or more curative-intent stereotactic radiotherapy courses. Int J Radiat Oncol Biol Phys 2009;73:832-7. https://doi.org/10.1016/j.ijrobp.2008.04.073
  21. Inoue T, Katoh N, Aoyama H, et al. Clinical outcomes of stereotactic brain and/or body radiotherapy for patients with oligometastatic lesions. Jpn J Clin Oncol 2010;40:788-94. https://doi.org/10.1093/jjco/hyq044
  22. Hird A, Chow E, Yip D, et al. After radiotherapy, do bone metastases from gastrointestinal cancers show response rates similar to those of bone metastases from other primary cancers? Curr Oncol 2008;15:219-25.
  23. Jang JW, Kay CS, You CR, et al. Simultaneous multitarget irradiation using helical tomotherapy for advanced hepatocellular carcinoma with multiple extrahepatic metastases. Int J Radiat Oncol Biol Phys 2009;74:412-8. https://doi.org/10.1016/j.ijrobp.2008.08.034
  24. Kim TG, Park HC, Lim DH, et al. Radiation therapy for bone metastases from hepatocellular carcinoma: effect of radiation dose escalation. J Korean Soc Ther Radiol Oncol 2011;29:63- 70. https://doi.org/10.3857/jkstro.2011.29.2.63
  25. Mahadevan A, Floyd S, Wong E, Jeyapalan S, Groff M, Kasper E. Stereotactic body radiotherapy reirradiation for recurrent epidural spinal metastases. Int J Radiat Oncol Biol Phys 2011;81:1500-5. https://doi.org/10.1016/j.ijrobp.2010.08.012
  26. Garg AK, Wang XS, Shiu AS, et al. Prospective evaluation of spinal reirradiation by using stereotactic body radiation therapy: The University of Texas MD Anderson Cancer Center experience. Cancer 2011;117:3509-16. https://doi.org/10.1002/cncr.25918
  27. Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009;114:589-95. https://doi.org/10.1182/blood-2009-02-206870
  28. Campos S, Presutti R, Zhang L, et al. Elderly patients with painful bone metastases should be offered palliative radiotherapy. Int J Radiat Oncol Biol Phys 2010;76:1500-6. https://doi.org/10.1016/j.ijrobp.2009.03.019
  29. Park HC, Seong J, An JH, Kim J, Kim UJ, Lee BW. Alteration of cancer pain-related signals by radiation: proteomic analysis in an animal model with cancer bone invasion. Int J Radiat Oncol Biol Phys 2005;61:1523-34. https://doi.org/10.1016/j.ijrobp.2004.12.070
  30. Chang EL, Shiu AS, Mendel E, et al. Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. J Neurosurg Spine 2007;7:151-60. https://doi.org/10.3171/SPI-07/08/151
  31. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76. https://doi.org/10.1053/ctrv.2000.0210
  32. Lutz S, Berk L, Chang E, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011;79:965-76. https://doi.org/10.1016/j.ijrobp.2010.11.026

Cited by

  1. FDG‐PET predicts outcomes of treated bone metastasis following palliative radiotherapy in patients with hepatocellular carcinoma vol.34, pp.7, 2011, https://doi.org/10.1111/liv.12487
  2. An 87-year-old patient with repeated oligorecurrences over six years whose disease were treated with radiotherapy alone vol.32, pp.4, 2014, https://doi.org/10.3857/roj.2014.32.4.266
  3. Feasibility and response of helical tomotherapy in patients with metastatic colorectal cancer vol.33, pp.4, 2011, https://doi.org/10.3857/roj.2015.33.4.320
  4. High dose and compartmental target volume may improve patient outcome after radiotherapy for pelvic bone metastases from hepatocellular carcinoma vol.7, pp.33, 2011, https://doi.org/10.18632/oncotarget.9767